- Trials with a EudraCT protocol (38)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
38 result(s) found for: Free recall.
Displaying page 1 of 2.
EudraCT Number: 2010-024543-33 | Sponsor Protocol Number: P64 | Start Date*: 2011-04-14 |
Sponsor Name:Maastricht University | ||
Full Title: Can memantine prevent memory impairment induced by MDMA in humans | ||
Medical condition: none | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006487-30 | Sponsor Protocol Number: 150662 | Start Date*: 2009-09-11 | |||||||||||
Sponsor Name:St. James's Hospital | |||||||||||||
Full Title: Differential Effects of donepezil and placebo in mild cognitive impairment and elderly controls. | |||||||||||||
Medical condition: Amnestic Mild Cognitive Impairment (aMCI) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004955-64 | Sponsor Protocol Number: E2090-S082-403 | Start Date*: 2017-04-21 |
Sponsor Name:Eisai Korea Inc. | ||
Full Title: A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function | ||
Medical condition: Epilepsy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2007-001975-12 | Sponsor Protocol Number: V00191 PO 202 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF | |||||||||||||
Full Title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel... | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) FI (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004537-16 | Sponsor Protocol Number: 29BRC19.0280 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:CHRU de Brest | |||||||||||||
Full Title: Comparison of an inhaled sedation strategy to an intravenous sedation strategy in ICU patients treated with invasive mechanical ventilation | |||||||||||||
Medical condition: Prevention of delirium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000307-17 | Sponsor Protocol Number: DIAN-TU-001 | Start Date*: 2014-01-08 |
Sponsor Name:Washington University in St. Louis | ||
Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ... | ||
Medical condition: Dominantly Inherited Alzheimer Disease (DIAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001749-13 | Sponsor Protocol Number: P04071 | Start Date*: 2005-02-22 |
Sponsor Name:AESCA Pharma GesmbH | ||
Full Title: Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy alone | ||
Medical condition: Patients with non small cell lung cancer (NSCLC) have a high risk of developing brain metastasis, up to 40% as evaluated in autopsy studies. These patients are often heavily symptomatic and their l... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-010067-16 | Sponsor Protocol Number: CN156018 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ... | |||||||||||||
Medical condition: ALZHEIMER DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004149-17 | Sponsor Protocol Number: 40346527ALZ1001 | Start Date*: 2019-06-07 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001591-11 | Sponsor Protocol Number: 3.4.11.049 | Start Date*: 2012-12-21 |
Sponsor Name:Erasmus MC | ||
Full Title: Symptomatic treatment of pollen related allergic rhinoconjunctivitis and the relation with asthma with children in the General practice | ||
Medical condition: Allergic Rhinitis Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001751-17 | Sponsor Protocol Number: IIBSP-DON-2022-43 | Start Date*: 2023-07-27 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005217-37 | Sponsor Protocol Number: I4O-MC-BACC(b) | Start Date*: 2012-08-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease | |||||||||||||
Medical condition: Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003288-24 | Sponsor Protocol Number: GRN163LMYF3001 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:Geron Corporation | |||||||||||||
Full Title: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/... | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003302-27 | Sponsor Protocol Number: ANAVEX2-73-AD-004 | Start Date*: 2020-01-22 | |||||||||||
Sponsor Name:Anavex Germany GmbH | |||||||||||||
Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD). | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004703-14 | Sponsor Protocol Number: ACT16404 | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chr... | |||||||||||||
Medical condition: Cutaneous Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021933-30 | Sponsor Protocol Number: EPU055 | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Maastricht University | |||||||||||||
Full Title: Effects of treated and untreated Allergic Rhinitis on Mood, Cognitive functions and Actual Driving Performance | |||||||||||||
Medical condition: Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005817-61 | Sponsor Protocol Number: iVAC-CLL01 | Start Date*: 2016-07-28 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: iVAC-CLL01: Patient-individualized peptide vaccination after first line therapy of CLL | |||||||||||||
Medical condition: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) after first line therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016504-22 | Sponsor Protocol Number: AFFiRiS006 | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:AFFiRiS AG | |||||||||||||
Full Title: A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/for... | |||||||||||||
Medical condition: Patients with early degree of Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) SK (Completed) CZ (Completed) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000860-90 | Sponsor Protocol Number: CRAD001M2304 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC)... | |||||||||||||
Medical condition: Refractory partial-onset seizures associated with tuberous sclerosis complex (TSC) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) NL (Completed) DE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) DK (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003532-73 | Sponsor Protocol Number: ADVANCE-AD04-001 | Start Date*: 2023-05-02 | ||||||||||||||||
Sponsor Name:ADvantage Therapeutics GmbH | ||||||||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE | ||||||||||||||||||
Medical condition: early Alzheimer’s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Prematurely Ended) DE (Completed) FR (Completed) AT (Trial now transitioned) BG (Completed) PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
